▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...
InnovationOpenLab

BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice

Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publicat...

Business Wire

LONDON: Regulatory News:

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the “2023 Annual Report”) and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “2024 AGM Notice”).

The 2023 Annual Report, the 2024 AGM Notice, the amended Remuneration Policy of the Company, the proxy form and any other meeting documentation are available on the Company’s website (www.benevolent.com/investors/general-meetings/) and at the Company’s registered office.

The shareholders entitled to participate and vote at the 2024 AGM will be those who are shareholders on the record date of 18 April 2024 at 24:00 (midnight) CEST.

About BenevolentAI

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

The Etna Valley will be a main European semiconductors hub

The EU ChipsJU program will fund the development of innovative semiconductors production lines in Catania, thanks to an international consortium led by…

Bending Spoons acquires StreamYard

The Italian tech company has entered into an agreement to buy the US based live-streaming and video-recording business

HR startup's market is on fire, ask to Factorial

Factorial secures $80M of Go-To-Market investment from General Catalyst to accelerate growth.

Awentia brings Italian Deep Tech to South America

From Imola, Awentia Agritech will take its Smart Agriculture technologies to Argentinian companies Ava Fruit, Doña Paula and Bodega A16

Most read

The Etna Valley will be a main European semiconductors hub

The EU ChipsJU program will fund the development of innovative semiconductors production lines in Catania, thanks to an international consortium led by…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!